Transition from Continuous Subcutaneous Insulin Infusion to IDeg-Based Regimens in Hospitalized T2DM Patients: A Single-Center Retrospective Analysis
Diabetes, Metabolic Syndrome and Obesity · 2026-01 · Volume 19 · 1-13
DOI: 10.2147/dmso.s557994 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Metabolic Syndrome and Obesity, 2026-01. Verfasst von Ruiqing Dong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, People's Republic of China. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Chinese patients with type 2 diabetes mellitus (T2DM) often initiate insulin therapy in the hospital, requiring rapid glycemic control and simplified post-discharge plans. Few clinical studies have focused on the transition protocols for continuous subcutaneous insulin infusion (CSII).
Objective
To evaluate the efficacy, safety, and patient satisfaction of transitioning from CSII to three treatment regimens: insulin degludec (IDeg), insulin degludec/insulin aspart (IDegAsp), or insulin degludec and liraglutide (IDegLira).
Methods
Clinical information and continuous glucose monitoring (CGM) data were retrospectively collected from 171 patients in a single center. Patient satisfaction and quality of life were assessed using standardized questionnaires in a three-month follow-up.
Results
After transition, mean glucose (MG) and glucose management indicator (GMI) decreased, while time in range (TIR) increased significantly. Coefficient of variation (CV) and time above range (TAR) decreased. Time below range (TBR) was unchanged in IDegAsp and IDegLira groups but slightly increased in the IDeg group (0.60% [0.00%, 1.60%] vs 1.10% [0.00%, 3.40%], P = 0.003). IDegAsp and IDegLira groups showed higher TIR and lower MG, GMI, CV, TAR, and TBR. 64.3% of IDegLira patients required one or fewer additional medications. Patient satisfaction was highest in the IDegLira group, with hypoglycemia avoidance, better weight management, fatigue prevention and less anxiety.
Conclusion
All three regimens enabled a smooth transition after CSII therapy. IDegAsp and IDegLira demonstrated superior glycemic control and reduced variability compared to IDeg. IDegLira was more convenient and associated with higher patient satisfaction. Keywords: type 2 diabetes mellitus, insulin degludec, insulin degludec/insulin aspart, insulin degludec and liraglutide, continuous glucose monitoring
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, People's Republic of China.
- School of Future Technology, Xi'an Jiaotong University, Xi'an, 710049, People's Republic of China.
- Department of Pain, The First Affiliated Hospital of Xinjiang Medical University, Urumqi City, 830017, People's Republic of China.
- Biobank, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, People's Republic of China.
ORCID-Profile: Lifan Gu, Bingyin Shi, Wei Qiang
Zitieren
APA
Dong, R., Gu, L., Li, H., Hu, Y., Liu, H., Kou, X., Zhao, Y., Zhao, M., Shi, B., Guo, H., & Qiang, W. (2026). Transition from Continuous Subcutaneous Insulin Infusion to IDeg-Based Regimens in Hospitalized T2DM Patients: A Single-Center Retrospective Analysis. Diabetes, Metabolic Syndrome and Obesity, Volume 19, 1-13. https://doi.org/10.2147/dmso.s557994
Vancouver
Dong R, Gu L, Li H, Hu Y, Liu H, Kou X, et al. Transition from Continuous Subcutaneous Insulin Infusion to IDeg-Based Regimens in Hospitalized T2DM Patients: A Single-Center Retrospective Analysis. Diabetes, Metabolic Syndrome and Obesity. 2026;Volume 19:1-13. doi:10.2147/dmso.s557994
BibTeX
@article{Dong2026,
author = {Dong, Ruiqing and Gu, Lifan and Li, Heping and Hu, Yuanna and Liu, Hui and Kou, Xuna and Zhao, Yukun and Zhao, Meng and Shi, Bingyin and Guo, Hui and Qiang, Wei},
title = {Transition from Continuous Subcutaneous Insulin Infusion to IDeg-Based Regimens in Hospitalized T2DM Patients: A Single-Center Retrospective Analysis},
journal = {Diabetes, Metabolic Syndrome and Obesity},
year = {2026},
volume = {Volume 19},
pages = {1--13},
doi = {10.2147/dmso.s557994}
}
EUVIMED